Iovance Biotherapeutics Inc. has announced the resignation of Jean-Marc Bellemin as Chief Financial Officer, effective June 30, 2025. Matthew W. Rosinack has been appointed as the interim Principal Financial Officer and Principal Accounting Officer. Rosinack has been with Iovance as Senior Vice President, Finance since September 2021 and has previous experience with Berkeley Lights, Inc., ZELTIQ Aesthetics, Inc., and FormFactor, Inc.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065781), on July 03, 2025, and is solely responsible for the information contained therein.